Connect Biopharma Releases Encouraging Long-Term Results for Rademikibart in Atopic Dermatitis Study

Connect Biopharma Holdings Limited CNTB, a clinical-stage biopharmaceutical company specializing in the research and development of immune modulators to combat severe autoimmune diseases and inflammation, has reported compelling long-term data from its pivotal trial conducted in China. The study focuses on their innovative drug, Rademikibart, aimed at treating moderate-to-severe atopic dermatitis (AD), a chronic inflammatory skin condition.

Study Highlights Efficacy and Endurance of Rademikibart

The trial's positive outcome reveals that an impressive rate of approximately 90% of patients administered with the rademikibart treatment on a once every four weeks (Q4W) schedule successfully maintained both the Investigator's Global Assessment (IGA) score of 0/1 and Eczema Area and Severity Index (EASI-75) results through the one-year mark (Week 52). This is a significant indicator of the continuous and sustained efficacy of the treatment regimen.

Long-term Benefits for Atopic Dermatitis Patients

The ongoing success of rademikibart showcased in this trial could symbolize a new horizon for individuals suffering from moderate-to-severe atopic dermatitis. The ability to maintain clear or almost clear skin alongside significant reduction in the severity and area of eczema, as demonstrated by the maintained IGA 0/1 and EASI-75 scores, may enable a better quality of life for patients enduring this chronic skin disease.

With headquarters situated in Taicang, China, CNTB is steadily establishing itself as an innovative force in the autoimmune treatment landscape. Both physicians and patients are keenly watching the advancements made by Connect Biopharma as it continues to report advancements in its clinical trials and pursue effective treatment modalities.

Biopharma, Rademikibart, Efficacy